Clinical Trials Browser

Phase 2 × INDUSTRY × 30 days × Clear all

NCT02365597 2026-06-05

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Phase 2 Active not recruiting

239 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT04133636 2026-06-05

CARTITUDE-2

Phase 2 Active not recruiting

Multiple Myeloma

NCT04258033 2026-06-05

KUNPENG

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT04325828 2026-06-05

YATAGARASU

Phase 2 Active not recruiting

31 enrolled 15 charts

Salivary Gland Neoplasms

NCT04634552 2026-06-05

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 1 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT04640623 2026-06-05

SunRISe-1

Phase 2 Active not recruiting

220 enrolled 1 FDA

Urinary Bladder Neoplasms

NCT05498428 2026-06-05

PALOMA-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05503797 2026-06-05

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Phase 2 Recruiting

Glioma

NCT05748171 2026-06-05

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05963074 2026-06-05

TAILOR

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06095505 2026-06-05

ALISCA-Lung1

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT06120140 2026-06-05

COCOON

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06500884 2026-06-05

Talisman

Phase 2 Recruiting

Multiple Myeloma

NCT06550895 2026-06-05

MonumenTAL-8

Phase 2 Active not recruiting

Multiple Myeloma

NCT06568939 2026-06-05

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06577025 2026-06-05

aMMbition

Phase 2 Active not recruiting

Multiple Myeloma

NCT06667076 2026-06-05

COPERNICUS

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06667908 2026-06-05

CONVERGE

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07007559 2026-06-05

ASPEN-09-03

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT07149857 2026-06-05

CARTITUDE-10

Phase 2 Recruiting

Multiple Myeloma

NCT07225621 2026-06-05

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

Phase 2 Recruiting

Glioblastoma

NCT07266441 2026-06-05

TRIlogy-3

Phase 2 Recruiting

Multiple Myeloma

NCT07326566 2026-06-05

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Phase 2 Recruiting

Brain Neoplasms, Central Nervous System Diseases, Glioblastoma, Glioma

NCT07353957 2026-06-05

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

Phase 2 Recruiting

Lung Neoplasms

NCT07359820 2026-06-05

ReFocus202

Phase 2 Recruiting

Other solid neoplasm

FGFR2 Gene Fusion/Rearrangement

NCT07475806 2026-06-05

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Recruiting

Muscle-invasive Bladder Cancer

NCT03816163 2026-06-04

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06140524 2026-06-04

LINKER-MGUS1

Phase 2 Recruiting

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

NCT06463665 2026-06-04

VIRO-25

Phase 2 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT06760819 2026-06-04

panSOHO

Phase 2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT07059845 2026-06-04

FLORENZA

Phase 2 Recruiting

Ovarian Neoplasms

NCT07169851 2026-06-04

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Phase 2 Recruiting

Nausea, Neoplasms, Vomiting, Drug-Related Side Effects and Adverse Reactions

NCT07269782 2026-06-04

A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07287150 2026-06-04

InavoPC

Phase 2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT07476287 2026-06-04

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07628062 2026-06-04

Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01009177 2026-06-03

Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)

Phase 2 Completed

Melanoma, Neoplasm Metastasis

NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Phase 2 Withdrawn

Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

NCT02519348 2026-06-03

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Phase 2 Active not recruiting

433 enrolled 26 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03899155 2026-06-03

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT04567420 2026-06-03

DARE

Phase 2 Recruiting

Breast Neoplasms

NCT05207670 2026-06-03

MorningSun

Phase 2 Active not recruiting

Lymphoma, Non-Hodgkin

NCT05546476 2026-06-03

PROACC-1

Phase 2 Completed

187 enrolled 24 charts

GastrointestinalThoracic

Anorexia, Cachexia, Carcinoma, Non-Small-Cell Lung, Fatigue, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Weight Loss

NCT06194448 2026-06-03

NEOLA

Phase 2 Active not recruiting

Lung Neoplasms

NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Phase 2 Active not recruiting

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT06745583 2026-06-03

A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

Phase 2 Recruiting

Neuroinflammatory Diseases, Alzheimer Disease, Lymphoma, Follicular, Neurodegenerative Diseases, Cognitive Dysfunction

NCT07002034 2026-06-03

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Phase 2 Recruiting

Adjustment Disorders, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Depression, Multiple Sclerosis, Neoplasms, Idiopathic Pulmonary Fibrosis

NCT07284420 2026-06-03

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Phase 2 Recruiting

Myasthenia Gravis

NCT07483554 2026-06-03

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

Phase 2 Recruiting

Gastrointestinal

CLDN18.2 Positive

NCT07622186 2026-06-03

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung